PostGraduate Assembly in Anesthesiology (PGA), New York City

December 7-11

Amercian Society of Anesthesiology (ASA) San Francisco, CA

 October 13-17

Health Connect Partners (HCP), Los Angeles, CA

October 1-3

Future Pharma, Boston, MA

September 26-28

Integrated Delivery Network Summit and Reverse Expo (IDN), Phoenix, AZ

September 17-19

SG2 Executive Summit, Chicago, IL

July 23-25

09 July 2018

Operating Update for the First Half 2018

02 July 2018

$30 Million Credit Facility with Hercules Technology Growth Capital Secured to Support Intended Commercialisation of BARHEMSYS™ in the US

LSX CEO Forum, London, England

June 27

American Society of Metabolic and Bariatric Surgery (ASMBS), New York City

June 14-16

Jefferies 2018 Healthcare Conference, New York City

June 5-8

2018 BIO international Convention, Boston, MA

June 4-7

American Society of Health-System Pharmacists (ASHP), Denver, CO

June 2-6

Bio€quity Europe, Ghent, Belgium

May 14-16

Society for Ambulatory Anesthesia (SAMBA), Miami, FL

May 3-5

American College of Obstetricins & Gynaecology (ACOG), Austin, TX

April 27-30

2018 World Congress on Regional Anesthesia & Pain Medicine (ASRA), New York City

April 19 - 21

11 April 2018

US Commercial Operations for BARHEMSYS™ (formerly BAREMSIS®) Expanded Four Key Appointments

15 March 2018

BARHEMSYS™ (formerly BAREMSIS®) Prevents Post-Operative Nausea & Vomiting In High-Risk Patients (published in Anesthesiology)

02 March 2018

Acacia Pharma - Prospectus

02 March 2018

Acacia Pharma Successfully Prices Its Initial Global Offering At Eur 3.60 Per Share Raising Eur 40 Million

19 February 2018

Acacia Pharma commences management roadshow and setting of the price range for its Initial Global Offering and listing on Euronext Brussels.

05 February 2018

Acacia Pharma Announces its Intention to Launch an Initial Global Offering and to List its Shares on Euronext Brussels

04 January 2018

FDA Acceptance Of NDA Filing For BAREMSIS® For The Management Of PONV

13 February 2017

Positive Results From 4th And Final Pivotal Phase 3 Trial Of BAREMSIS® For Rescue Treatment Of PONV